RecruitingPhase 2NCT06047262

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With Type 2 Diabetes Mellitus

Sponsor

Marc Donath

Enrollment

300 participants

Start Date

Jul 9, 2024

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a new pharmacological option for diabetes management with potential as an anti-inflammatory agent to also address micro- and macro-vascular risk and complications from diabetes.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests dapansutrile — a drug that blocks a specific inflammation-causing protein (called NLRP3) — in people with type 2 diabetes who have high levels of inflammation. The hope is that reducing this specific kind of inflammation may improve blood sugar control and reduce diabetes complications. **You may be eligible if...** - You are 18 or older with a type 2 diabetes diagnosis for at least 3 months - Your HbA1c is between 7.7% and 11.0% - Your blood inflammation marker (hsCRP) is elevated (≥1.5 mg/L) - Your BMI is between 25 and 40 kg/m² - Your heart, kidney, and liver are in acceptable condition **You may NOT be eligible if...** - You have type 1 diabetes or other types of diabetes - You have had a recent heart attack or stroke - You have severe kidney or liver disease - You are currently using immunosuppressive medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.